Cellectar Biosciences Toekomstige groei
Future criteriumcontroles 5/6
Cellectar Biosciences is forecast to grow earnings and revenue by 70.7% and 60% per annum respectively while EPS is expected to grow by 71.2% per annum.
Belangrijke informatie
70.7%
Groei van de winst
71.2%
Groei van de winst per aandeel
| Biotechs winstgroei | 36.4% |
| Inkomstengroei | 60.0% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 11 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 113 | 15 | N/A | N/A | 3 |
| 12/31/2025 | 51 | -25 | N/A | N/A | 3 |
| 12/31/2024 | N/A | -63 | N/A | N/A | 3 |
| 6/30/2024 | N/A | -48 | -46 | -45 | N/A |
| 3/31/2024 | N/A | -57 | -39 | -39 | N/A |
| 12/31/2023 | N/A | -38 | -33 | -32 | N/A |
| 9/30/2023 | N/A | -38 | -31 | -30 | N/A |
| 6/30/2023 | N/A | -32 | -29 | -29 | N/A |
| 3/31/2023 | N/A | -30 | -28 | -27 | N/A |
| 12/31/2022 | N/A | -29 | -25 | -25 | N/A |
| 9/30/2022 | N/A | -27 | -23 | -22 | N/A |
| 6/30/2022 | N/A | -25 | -22 | -22 | N/A |
| 3/31/2022 | N/A | -24 | -23 | -23 | N/A |
| 12/31/2021 | N/A | -24 | -23 | -23 | N/A |
| 9/30/2021 | N/A | -22 | -22 | -22 | N/A |
| 6/30/2021 | N/A | -20 | -19 | -19 | N/A |
| 3/31/2021 | N/A | -17 | -15 | -15 | N/A |
| 12/31/2020 | N/A | -15 | -14 | -14 | N/A |
| 9/30/2020 | N/A | -15 | -13 | -13 | N/A |
| 6/30/2020 | N/A | -15 | -13 | -13 | N/A |
| 3/31/2020 | N/A | -14 | -12 | -12 | N/A |
| 12/31/2019 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2019 | N/A | -15 | -12 | -12 | N/A |
| 6/30/2019 | N/A | -16 | -12 | -11 | N/A |
| 3/31/2019 | N/A | -16 | -11 | -11 | N/A |
| 12/31/2018 | N/A | -15 | -12 | -11 | N/A |
| 9/30/2018 | N/A | -17 | -12 | -12 | N/A |
| 6/30/2018 | N/A | -15 | -11 | -11 | N/A |
| 3/31/2018 | N/A | -16 | N/A | -11 | N/A |
| 12/31/2017 | N/A | -15 | N/A | -11 | N/A |
| 9/30/2017 | N/A | -15 | N/A | -11 | N/A |
| 6/30/2017 | N/A | -14 | N/A | -10 | N/A |
| 3/31/2017 | N/A | -13 | N/A | -9 | N/A |
| 12/31/2016 | N/A | -9 | N/A | -8 | N/A |
| 9/30/2016 | N/A | -3 | N/A | -7 | N/A |
| 6/30/2016 | N/A | -2 | N/A | -7 | N/A |
| 3/31/2016 | N/A | -2 | N/A | -8 | N/A |
| 12/31/2015 | N/A | -5 | N/A | -8 | N/A |
| 9/30/2015 | N/A | -10 | N/A | -9 | N/A |
| 6/30/2015 | N/A | -8 | N/A | -9 | N/A |
| 3/31/2015 | N/A | -7 | N/A | -9 | N/A |
| 12/31/2014 | N/A | -8 | N/A | -9 | N/A |
| 9/30/2014 | N/A | -9 | N/A | -9 | N/A |
| 6/30/2014 | N/A | -10 | N/A | -10 | N/A |
| 3/31/2014 | N/A | -10 | N/A | -10 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: NV4 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Winst versus markt: NV4 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: NV4 is expected to become profitable in the next 3 years.
Omzet versus markt: NV4's revenue (60% per year) is forecast to grow faster than the German market (5.5% per year).
Hoge groei-inkomsten: NV4's revenue (60% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if NV4's Return on Equity is forecast to be high in 3 years time